Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Breast-conserving surgery plus radiotherapy offers better survival than mastectomy with or without radiation after accounting for comorbidity and socioeconomic factors

Phase I NRG-BR001 trial findings suggest that stereotactic body radiotherapy is not associated with dose-limiting toxicities in patients treated for oligometastases

Cancer patients should be given their second dose of the BNT162b2 vaccine 21 days after their first to ensure protection from SARS-CoV-2 infection

Carboplatin–paclitaxel is superior to single-agent carboplatin for FIGO stage III–IV ovarian cancer in women with a high Geriatric Vulnerability Score

Adding alisertib to paclitaxel chemotherapy may improve progression-free survival for patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer

Non-small-cell lung cancer response to immune checkpoint inhibitor therapy may be linked to the number of chromosomal arm alterations present

Phase III data suggest that combining copanlisib with rituximab could be an option for patients with indolent non-Hodgkin lymphoma who have progressed on at least one prior rituximab-based therapy

 Patients with relapsed or refractory B-cell lymphomas may benefit from treatment with bispecific CAR T-cell therapy directed against CD19 and CD20